Chemo drug combination for advanced stomach or esophagus cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent to share your medical information (HIPAA authorization).
- Your performance is good enough for treatment (ECOG 0 to 2).
- Your cancer is confirmed advanced or metastatic stomach/esophagus adenocarcinoma, and you already have known HER2 and PDL1 test results.
- Your scan shows measurable cancer that can be tracked (RECIST).
- You have not had prior “systemic” drug treatment for advanced cancer (but prior earlier treatment is allowed if the cancer came back 6+ months after).
- Your blood counts and organ function meet safety lab limits within 14 days before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
This trial tests a combination of three drugs for advanced stomach or esophagus cancer that hasn't been treated much. The goal is to see if this combination helps shrink or control the cancer.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.